ArticleScientific reports2026
Prevalence and genotypic distribution of high-risk human papillomavirus in primary breast tumors in Western Uganda: a case-control study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Although in vitro studies have demonstrated that HPV can immortalize mammary epithelial cells, its contribution to breast carcinoma development in living organisms remains debatable. Reports on HPV detection in breast tumors vary widely across regions, and data from East Africa are limited. This study investigated the prevalence and genotypic distribution of high-risk HPV in breast tumors in Western Uganda. This retrospective case-control study was conducted using archived formalin-fixed paraffin-embedded tissue specimens from 66 breast carcinomas (cases) and 42 fibroadenomas (controls) diagnosed between 2012 and 2018 at Mbarara Regional Referral Hospital. High-risk HPV DNA was detected using real-time polymerase chain reaction (rRT-PCR), and genotyping was performed using the AmpliSens HPV HCR genotype-titre-FRT PCR kit. To validate the assay, cervical squamous cell carcinoma samples served as technical controls. Associations between HPV prevalence and breast carcinoma were assessed using chi-square tests and odds ratios. High-risk HPV DNA was detected in 25 of 108 breast tumor specimens (23.1%). The prevalence of HPV was 24.2% (16/66) in breast carcinomas and 21.4% (9/42) in fibroadenomas, with no statistically significant difference between cases and controls (p = 0.735; OR = 1.17, 95% CI: 0.46-2.97). Detected HPV genotypes included 16, 18, 33, 39, 45, 51, 56, and 58. HPV genotype 39 was the most frequently detected genotype in both breast carcinomas (50% of HPV-positive cases) and fibroadenomas (44.4% of HPV-positive cases). High-risk HPV was detected in all cervical cancer control specimens, confirming assay validity. These findings indicate that although high-risk HPV DNA was detected in breast tissue in this population, its presence alone does not support a primary causal role in breast carcinogenesis. Further studies incorporating viral load and transcriptional activity are needed to clarify the biological relevance of HPV in breast tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.